GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent

GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion. However, not all GPR40 agonists are the same. Partial agonists lower glucose through direct effects on the pancreas, whereas GPR40 AgoPAMs may incorporate additional therapeutic effects through increases in insulinotrophic incretins secreted by the gut. Here we describe how GPR40 AgoPAMs stimulate both insulin and incretin secretion in vivo over time in diabetic GK rats. We also describe effects of AgoPAMs in vivo to lower glucose and body weight beyond what is seen with partial GPR40 agonists in both the acute and chronic setting. Further comparisons of the glucose lowering profile of AgoPAMs suggest these compounds may possess greater glucose control even in the presence of elevated glucagon secretion, an unexpected feature observed with both acute and chronic treatment with AgoPAMs. Together these studies highlight the complexity of GPR40 pharmacology and the potential additional benefits AgoPAMs may possess above partial agonists for the diabetic patient.

[1]  M. Erion,et al.  Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy , 2017, Science.

[2]  A. Howard,et al.  GPR40 reduces food intake and body weight through GLP-1. , 2017, American journal of physiology. Endocrinology and metabolism.

[3]  A. Howard,et al.  Design and Synthesis of Novel, Selective GPR40 AgoPAMs. , 2017, ACS medicinal chemistry letters.

[4]  Nicholas J Agard,et al.  Synthesis of the GPR40 Partial Agonist MK-8666 through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction. , 2016, Organic letters.

[5]  M. Erion,et al.  Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus. , 2016, American journal of physiology. Endocrinology and metabolism.

[6]  T. Schwartz,et al.  GPR40 (FFAR1) – Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo , 2014, Molecular metabolism.

[7]  K. Takeuchi,et al.  A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 , 2013, PloS one.

[8]  C. Burant.  Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes , 2013, Diabetes Care.

[9]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[10]  S. Wong,et al.  Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1 , 2013, Molecular and Cellular Endocrinology.

[11]  M. Jensen,et al.  The Role of Voltage-Gated Potassium Channels Kv2.1 and Kv2.2 in the Regulation of Insulin and Somatostatin Release from Pancreatic Islets , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[12]  Sean P. Brown,et al.  Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor , 2012, Molecular Pharmacology.

[13]  Sean P. Brown,et al.  A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents , 2012, PloS one.

[14]  J. Holst,et al.  Regulation of glucagon secretion by incretins , 2011, Diabetes, obesity & metabolism.

[15]  Masahiro Ito,et al.  Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. , 2010, ACS medicinal chemistry letters.

[16]  Michael E. Lassman,et al.  Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.

[17]  H. Davis,et al.  Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic Disease , 2008, Diabetes.

[18]  Yun-ping Zhou,et al.  Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice , 2008, Diabetes.

[19]  J. Fornwald,et al.  Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules , 2006, British journal of pharmacology.

[20]  S. Hinuma,et al.  GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[21]  S. Burgess,et al.  Glucose production, gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. , 2004, Analytical biochemistry.

[22]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Grodsky,et al.  Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. , 1974, The Journal of clinical investigation.

[24]  P. Lacy,et al.  Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas , 1967, Diabetes.

[25]  Michael E. Lassman,et al.  Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test. , 2016, Clinical chemistry.

[26]  Zhiguang Guo,et al.  Evaluating insulin secretagogues in a humanized mouse model with functional human islets. , 2013, Metabolism: clinical and experimental.

[27]  M. Erion,et al.  Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents , 2012, Biopolymers.